copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Treatment protocols for esophagogastric cancer - UpToDate The following material represents a subset of chemotherapy and immunotherapy regimens that are used for the treatment of patients with esophageal and gastric cancer, both in the adjuvant neoadjuvant setting and for advanced disease
Benefit of First-Line Pembrolizumab Plus Chemotherapy in Esophageal . . . These findings reinforce the status of pembrolizumab plus chemotherapy as a first-line standard of care for advanced esophageal cancer Updated results raise questions on whether first-line pembrolizumab chemotherapy is appropriate for all patients with esophageal cancer regardless of PD-L1 status
Gastric and Esophageal Cancers: Guidelines Updates In addition to pembrolizumab and nivolumab, new treatment options include trastuzumab-deruxtecan (T-DXd), ramucirumab, and trifluridine tipiracil These agents convey varying degrees of benefit depending on treatment line, PD-L1 expression, HER2 expression, and tumor histology
Efficacy of pembrolizumab in advanced esophageal carcinoma: A . . . We performed a pooled analysis to assess the efficacy of pembrolizumab in esophageal carcinoma (EC) and to compare it with chemotherapy alone Methods: We conducted a systemic literature search, using PubMed, EMBASE, and ClinicalTrials gov, till July 30, 2024
Pembrolizumab Plus Chemotherapy in Advanced Esophageal Cancer: Good . . . This interim analysis of the phase III KEYNOTE-590 trial showed that the addition of pembrolizumab to platinum fluorouracil in the first-line setting resulted in improved overall and progression-free survival in patients with advanced esophageal and GEJ carcinomas
Immune checkpoint inhibitors for esophageal cancer: are we moving in . . . Advanced, metastatic esophageal cancer is a disease traditionally treated with systemic chemotherapy, an approach that is largely palliative with limited durable benefit Recently, several trials have demonstrated improved outcomes in this patient population using immune checkpoint inhibitors
Pembrolizumab for Heavily Pretreated Patients With Advanced Carcinoma . . . It shows the antitumor activity of pembrolizumab in patients with metastatic esophageal cancer in a single-arm, nonrandomized study Randomized phase studies evaluating pembrolizumab in patients with metastatic esophageal cancer in the first- and second-line setting are ongoing
Gastric and Esophageal Cancers: Guidelines Updates In addition to pembrolizumab and nivolumab, new treatment — options include trastuzumab-deruxtecan (T-DXd), ramucirumab, and trifluridine tipiracil These agents convey varying degrees of bene fit de-pending on treatment line, PD-L1 expression, HER2 expression, and tumor histology